With a detailed data drop that AstraZeneca’s R&D chief describes as an internal “science success story,” the British Big Pharma has secured an FDA priority review for what it believes could become a flagship biologic in chronic obstructive pulmonary disease.
- Home |
- AZ’s R&D chief Barr touts internal ‘science success story’ after IL-33 antibody’s stellar showing in COPD
AZ’s R&D chief Barr touts internal ‘science success story’ after IL-33 antibody’s stellar showing in COPD
- September 8, 2026
Recent Posts
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
- Cenovus to build oil sands business via Athabasca acquisition
- Centalion acquires Haynesville gas assets from Silver Hill
